The PARP Inhibitor AZD2281 (Olaparib) Induces Autophagy/Mitophagy in BRCA1 and BRCA2 Mutant Breast Cancer Cells

International Journal of Oncology - Greece
doi 10.3892/ijo.2015.3003
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Spandidos Publications

Related search

Reversion and Non-Reversion Mechanisms of Resistance to PARP Inhibitor or Platinum Chemotherapy in BRCA1/2-mutant Metastatic Breast Cancer

2019English

PPARγ Activation Induces Autophagy in Breast Cancer Cells

International Journal of Biochemistry and Cell Biology
BiochemistryCell Biology
2009English

Risk Assessment for Hereditary Breast Cancer: BRCA1 and BRCA2

Canadian Oncology Nursing Journal
2010English

Screening BRCA1 and BRCA2 Mutation Carriers for Breast Cancer

Cancers
Cancer ResearchOncology
2018English

PARP Inhibitor Treatment in Ovarian and Breast Cancer

Current Problems in Cancer
Cancer ResearchOncology
2011English

Treatment of Breast Cancer 2 (BRCA2)-mutant Follicular Dendritic Cell Sarcoma With a Poly ADP-ribose Polymerase (PARP) Inhibitor: A Case Report

BMC Research Notes
BiochemistryMedicineGeneticsMolecular Biology
2016English

Hereditary Breast Cancer in Moroccan Populations: BRCA1 & BRCA2 at the Glance

Journal of Genetic Syndromes & Gene Therapy
2014English

Plasma Osteoprotegerin and Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

Oncotarget
Oncology
2016English

PARP Inhibitor Veliparib and HDAC Inhibitor SAHA Synergistically Co-Target the UHRF1/BRCA1 DNA Damage Repair Complex in Prostate Cancer Cells

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy